A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Clinical Trial Grant
Awarded By
Argenx BV
Start Date
May 12, 2026
End Date
October 5, 2035
Awarded By
Argenx BV
Start Date
May 12, 2026
End Date
October 5, 2035